<DOC>
	<DOC>NCT01680952</DOC>
	<brief_summary>This study will compare the efficacy and safety of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate mofetil in Kidney Transplant Patients.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Male or female patients aged over 20 years Patient who is judged would have the benefits of the Extended Release Tacrolimus (Advagraf®)treatment by the investigator Patients has given written informed consent Patient is a recipient of primary or recipient of primary (a living kidney transplant, a cadaveric donor.) Patients has received an ABO compatible donor kidney. Complementdependent Cytotoxic Crossmatch: CDC) result: negative Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization Patient has previously received an organ transplant other than a kidney. Patient has a known hypersensitivity to tacrolimus, Sirolimus (Rapamune®),Mycophenolate mofetil. Desensitization HLAidentical Heart Disease; Heart failure (symptom, EF &lt;45%) Lung Disease; Significant chronic obstructive pulmonary disease, restrictive lung disease Patient has an uncontrolled concomitant infection (including Hepatitis B, Hepatitis C) or any other unstable malignant tumor history in the 5years prior to enrollment. (except,squamous cell carcinoma) Patient has received a kidney transplant from nonheart beating donor Cold ischemic time &gt; 30hrs Elevated AST and/or ALT levels greater than 3 times the upper value of the normal range of the investigational site (ANC)&lt;1,500/mm3, (WBC)&lt;2,500/ mm3, (PLT)&lt;100,000/ mm3 ATG: Antithymocyte globulin induction Medical condition that could interfere with the study objectives. Patient is currently taking or has been taking an investigational products in the 30 days prior to enrollment. Patient is currently taking or has been taking an prohibited medications in the 28 days prior to enrollment. Patient who is judged not to be adequate by the investigator owing to other reasons Patient is pregnant or lactating. Recipient or donor is known to be seropositive for human immunodeficiency virus.(HIV)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>RECORD study</keyword>
</DOC>